Wikidata

(Q50718484)

English

Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.

scientific article published on 24 February 2014

In more languages

Statements

title
Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. (English)
1 reference
stated in
Europe PubMed Central
PubMed ID
24567430
retrieved
18 March 2018
reference URL
http://europepmc.org/abstract/MED/24567430

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q50718484&oldid=1251060718"